Sanorin drops Nazal. children 0.05% 10ml vial, cap.

Description

Composition
Active substance:
10 ml of solution contains: naphazoline nitrate 0.005g ;.
Excipients:
Boric acid 0.170 g, 0.010 g of methyl parahydroxybenzoate, ethylenediamine q.s. (About 0.0004 g), purified water to 10 ml.
Description:
Transparent colorless liquid, odorless.
Product form:
The drops or spray 0.05% 0.05%
10 ml vial.
Contraindications
Children under 3 years of age; Hypersensitivity to naphazoline or any of the components. chronic rhinitis; atrophic rhinitis; closure glaucoma; severe eye disease; –arterial hypertension; pronounced atherosclerosis; tachycardia; hyperthyroidism; diabetes; simultaneous MAO inhibitors and up to 14 days after their application.
Carefully.
The drug Sanorin should be used with caution in severe cardiovascular disease (coronary heart disease), pheochromocytoma, as well as during pregnancy and breastfeeding period, a need for caution during general anesthesia with the use of anesthetics that increase myocardial sensitivity to sympathomimetics (eg, halothane) , especially in patients with bronchial asthma patients.
Dosage
0.5 mg / ml
Indications
Acute rhinitis of various etiology;
Otitis media – as an additional means for reducing mucosal swelling nasopharynx;
sinusitis;
evstahiit.
Interaction with other drugs
With the simultaneous application of the drug with MAO inhibitors or tricyclic antidepressants (and within 14 days after their application) may increase the blood pressure due to the release of catecholamines deposited under naphazoline. Therefore, use is contraindicated Sanorin drug simultaneously with MAO inhibitors and for 14 days after their withdrawal.
Naphazoline slows the absorption of local anesthetics, which leads to an increase in the duration of their action.
Overdose
symptoms:
Nervousness, excessive sweating, headache, tremor, tachycardia, palpitations, increased blood pressure, and possibly nausea, cyanosis, fever, convulsions, heart failure, pulmonary edema, respiratory and mental disorders. In case of depression of the central nervous system are observed bradycardia, weakness, drowsiness, reduction in body temperature, sweating, collapse, apnea and coma.
Treatment:
Lifting drug symptomatic therapy.
Children are more vulnerable to side effects of the drug, so the risk of overdose in children is higher than in adults.
pharmachologic effect
Pharmacological group:
Decongestant agent – alpha-agonists.
Pharmacological properties:
Alfa adrenomimeticheskoe, vasoconstrictor, decongestant.
Pharmacodynamics:
Naphazoline relates to alpha2-agonists with a direct stimulating effect on alpha-adrenergic receptors of the sympathetic nervous system. Intranasal administration provides a rapid, pronounced and prolonged vasoconstrictor effect on the blood vessels of the nasal mucosa, nasal cavity and paranasal sinuses of the nose -Reduces edema and hyperemia, thereby improving the permeability of the nasal passages and nasal breathing is facilitated. At the same time restores patency of the Eustachian tubes.
The therapeutic effect occurs, usually within 5 min after injection and lasts for 4-6 hours.
Pharmacokinetics:
on the distribution of data, metabolism and elimination nafazolina person does not have.
Pregnancy and breast-feeding
If necessary, use the drug during pregnancy and lactation (breastfeeding) should evaluate the potential benefits of therapy for the mother and the potential risk to the fetus.
Data on penetration nafazolina through the placental barrier and also in breast milk is not available.
side effects
Classification of frequency of adverse reactions to the World Health Organization (WHO) on the development of frequency: very common (> / = 1/10), common (> / = 1/100 and
special instructions
You should avoid long-term use and overdose, especially in children.
Long term use of drugs intended for the removal of mucosal edema can lead to development of secondary atrophy and subsequent edema of the nasal mucosa.
Patients using high doses of drugs should be monitored specialist about the possible occurrence of cardiovascular and neurological side effects (palpitations, hypertension, arrhythmia, headache, dizziness, drowsiness or insomnia).
The medicament contains Methyl parahydroxybenzoate which may cause allergic reactions (possibly delayed).
Because of the potential for adverse effects to the cardiovascular system and nervous system, do not exceed the recommended dose.
Effects on ability to drive and / or other mechanisms
The drug has no effect or little effect on the ability to drive vehicles and other potentially hazardous activities that require high concentration and psychomotor speed reactions taking into account the profile of side effects.
Storage conditions
Store in original container at a temperature not higher than 25 C. Do not freeze!
Keep out of the reach of children.
Dosing and Administration
Children aged 3 to 6 years appoint 1-2 injection in children aged 6 to 15 years – 2 Sanorin injection of the drug in each nostril.
Sanorin drug is injected into both nostrils 3 times per day. Between the individual injections should be observed interval of at least 4 hours.
Duration of treatment is not more than 3 days. If nasal breathing easier, the application Sanorin preparation can be completed earlier. Repeated use of the drug is possible in a few days after discontinuation of therapy.
When first using the drug Sanorin nasal spray for children is recommended several times to press the spray device, until a compact cloud of spray.
Before starting to use, remove the protective cap, a bottle held in a vertical position, the end portion of the spray device to enter into the nasal passage, then quickly and sharply to press the applicator. Immediately after the injection is recommended to breathe a little nose.
After use of the drug should be closed protective cap applicator.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist